Aurigene Oncology Limited, a subsidiary of Dr. Reddys Laboratories, reported promising Phase 1 results for its CAR-T cell therapy for multiple myeloma, with 100% clinical response from 8 heavily pre-treated patients, and received approval to start Phase 2.